Sanofi buys U.S. cancer firm for up to $500 million

PARIS (Reuters) – Sanofi-Aventis has agreed to buy private U.S. cancer specialist BiPar Sciences Inc. in the latest bolt-on acquisition by the French drugmaker.

Leave a Reply